<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11863066</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.1439</article-id><article-id pub-id-type="other">EPV0814</article-id><article-id pub-id-type="pii">S0924933824014391</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Viewing</subject></subj-group></article-categories><title-group><article-title>Haematological alterations in the context of olanzapine treatment</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Serra</surname><given-names>B.</given-names></name><xref rid="aff3171" ref-type="aff"/><xref rid="cor1289" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ramis</surname><given-names>D.</given-names></name><xref rid="aff3171" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Catal&#x000e1;n</surname><given-names>R.</given-names></name><xref rid="aff3171" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Llorca</surname><given-names>V.</given-names></name><xref rid="aff3171" ref-type="aff"/></contrib></contrib-group><aff id="aff3171"><institution>Institut Cl&#x000ed;nic de Neuroci&#x000e8;ncies, Hospital Cl&#x000ed;nic de Barcelona</institution>, <city>Barcelona</city>, <country>Spain</country></aff><author-notes><corresp id="cor1289"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="1414">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S691</fpage><lpage>S692</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824014391a.pdf"/><abstract><sec id="sec7748"><title>Introduction</title><p>Haematological alterations, especially in the red blood cell series, are a rare adverse effect of olanzapine treatment. A 64-year-old female patient with a diagnosis of long-standing schizophrenia was admitted to the psychiatric room for psychotic decompensation and leukopenia in control laboratory tests.&#x000a0;She had a history of mild psoriasis, allergy to sulphonamides and infectious bursitis nine years earlier secondary to neutropenia due to clozapine. On previous admission, episodes of anaemia and neutropenia related to increased doses of olanzapine were observed. On current admission, a new episode of anaemia and neutropenia occurred with doses of up to 20 mg/day of olanzapine, hemoglobin levels of 63g/L ann neutrophil count of 0,8*10^9 neutrophils/l were detected.</p></sec><sec id="sec7749"><title>Objectives</title><p>Report a very rare but serious adverse effect in patients treated with olanzapine.</p></sec><sec id="sec7750"><title>Methods</title><p>Haematological analysis were periodically carried out from 2009 to 2023.</p><p>A complete study was carried out with parameters of haemolysis, autoimmunity, a pharmacogenetic study and a myelogram.</p></sec><sec id="sec7751"><title>Results</title><p>The autoimmunity and haemolysis study excluded an autoimmune or haematological illness that could justify the haematological alterations.</p><p>The myelogram showed normal cellularity.</p><p>The pharmacogenetic study showed no relevant alterations.</p><p>
<bold>Image:</bold></p><p>
<fig position="float" id="fig0158"><graphic xlink:href="S0924933824014391-FIG0158" position="anchor"/></fig>
</p><p>
<bold>Image 2:</bold></p><p>
<fig position="float" id="fig0159"><graphic xlink:href="S0924933824014391-FIG0159" position="anchor"/></fig>
</p></sec><sec id="sec7752"><title>Conclusions</title><p>The case was classified as a non-immune haemolytic anaemia secondary to olanzapine and improved with withdrawal of the drug.</p></sec><sec id="sec7753"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>